Efficacy, Dose Reduction, and Resistance to High-Dose Fluticasone in Patients With Eosinophilic Esophagitis - Butz, Bridget K.; Wen, Ting; Gleich, Gerald J.; Furuta, Glenn T.; Spergel, Jonathan; King, Eileen; Kramer, Robert E.; Collins, Margaret H.; Stucke, Emily; Mangeot, Colleen; Jackson, W. Daniel; O'Gorman, Molly; et al. (Gastroenterology (New York, N.Y. 1943), 2014)
Keywords: Administration, Oral; Adolescent; Adult; Androstadienes - administration & dosage; Androstadienes - adverse effects; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - adverse effects; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Dysphagia; Eosinophilic Esophagitis - diagnosis; Eosinophilic Esophagitis - drug therapy; Eosinophilic Esophagitis - genetics; Fluticasone; Gastroenterology and Hepatology; Gene Expression Profiling; Gene Expression Regulation; Humans; Inflammation; Remission Induction; Severity of Illness Index; Steroids; Time Factors; Treatment; Treatment Outcome; United States; Young Adult; United States; PR; AE; PPI; Inflammation; FP; CFR; CR; EDP; CCHMC; Treatment; Dysphagia; EoE; Steroids; BMI; HPF; Code of Federal Regulations; partial remission; Eosinophilic Esophagitis Diagnostic Panel; high-power field; body mass index; adverse event; complete remission; Cincinnati Children's Hospital Medical Center; eosinophilic esophagitis; fluticasone propionate; proton-pump inhibitor